Evaluation of the Value of Cerebral Perfusion Scintigraphy in the Study of Post-stroke Fatigability

NCT03543280 | Unknown

• 1 other identifier: 6787
• Study Type: observational
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

At present there is no consensus for post-stroke imaging except for the realization of early cerebral CT at 24 hours post-thrombolysis. The use of cerebral perfusion scintigraphy would predict the course of a stroke. Indeed, it has been shown that a good perfusion is linked to a good evolution of the neurological deficit. This test is used routinely to evaluate cerebral perfusion in patients with stroke. This technique was also used to study the mechanisms of post-stroke aphasia and to highlight neuronal disconnections after stroke, a reflection of the functioning of neural networks. Neuropsychological tests are almost always done at 3 months. Fatigue is studied: PSF scale at 3 months, 6 months and 2 years. Research needs to be continued in this area because the pathophysiology remains unknown and the symptoms are disabling for patients. Using cerebral perfusion imaging would bring elements of understanding of this mechanism and ultimately improve the management of patients.

Conditions

Fatigability Post Stroke

Keywords

fatigability post stroke; post stroke; high-speed CT; MRI

Outcome Measures

Primary Outcomes (1)

• Evaluate fatigue symptoms in stroke patients

  After the period following a stroke: 1 month

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Patients with transient ischemic attack, stroke, dissection, TVC

You may qualify if:

• Patients: 18 to 60 years old at the initial diagnosis
• Admission for transient ischemic attack, stroke, dissection, TVC
• RANKIN less than or equal to 2
• Neuropsychological tests at +3 months: MoCA\> 26 (to eliminate cognitive deteriorations too important for the good realization of the battery)
• Absence of psychiatric history
• Absence of psychotropic medication
• No history of stroke
• No complaint of pre-stroke fatigue
• Having signed the consent form

You may not qualify if:

• Impossibility of giving the subject or his family enlightened information (subject in emergency situation, difficulties in understanding the subject, etc.)
• Subject under the protection of justice
• Subject under guardianship or curatorship
• Refusal of the patient to participate in the study

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service de Biophysique et de Médecine Nucléaire

Strasbourg, 67098, France

RECRUITING

Central Study Contacts

Izzie Jacques NAMER, MD, PhD

CONTACT

33 3 88 12 75 50; Izzie.Jacques.NAMER@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 26, 2018
• First Posted: June 1, 2018
• Study Start: February 23, 2018
• Primary Completion: February 1, 2019
• Study Completion: February 1, 2019
• Last Updated: June 1, 2018

Record last verified: 2018-02

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)